Precipio, INC 10-Q quarterly reports

Precipio, a cancer diagnostics company, reported significant revenue growth in Q3 2025 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Precipio, Inc. reported a net income of $74,000 for Q2 2025, driven by a 27% increase in net sales and non-recurring income, despite ongoing operating losses and significant accumulated deficit.

Precipio Inc. saw a significant revenue increase in the first quarter of 2025, but faces ongoing concerns about its ability to continue as a going concern.

Precipio Inc. saw a revenue increase in Q3 2024, driven by higher diagnostic testing volumes, but ongoing losses and a working capital deficit raise concerns about its financial stability.

Precipio Inc. saw a significant increase in diagnostic testing revenue in the second quarter of 2024, driven by a 92% increase in cases processed, but continues to face financial challenges.

Precipio Inc. saw a 22% increase in net sales in Q1 2024 compared to Q1 2023, driven by higher diagnostic testing volumes, but the company still faces substantial doubt about its ability to continue as a going concern.